Skip to main content

Table 1 Effect of Doxorubicin (DOX) and different treatments of AHE on Liver Function tests (LFTs)

From: Effect of Acacia hydaspica R. Parker extract on lipid peroxidation, antioxidant status, liver function test and histopathology in doxorubicin treated rats

Treatment (mg/kg)

ALT (U/l)

AST (U/l)

ALP (U/l)

LDH (U/l)

Total bilirubin (TB mg/dl)

Direct bilirubin (DB mg/dl)

Control

44.63 ± 0.491b

72.83 ± 0.120b

120.7 ± 0.333b

48.62 ± 0.232 b

0.92 ± 0.015b

0.303 ± 0.037b

DOX

139.80 ± 0.336a

191.0 ± 0.577a

355.8 ± 0.120a

171.10 ± 0.358 a

1.84 ± 0.016a

0.546 ± 0.017a

AHE alone

44.57 ± 0.233b

72.63 ± 0.186b

120.7 ± 0.208b

48.57 ± 0.203 b

0.917 ± 0.013b

0.300 ± 0.036b

DOX + AHE (200)

79.62 ± 0.523a, b, d

135.9 ± 0.133a, b, d

211.2 ± 0.441a, b, d

98.97 ± 0.548a, b, d

1.45 ± 0.023a, b, d

0.443 ± 0.009a*

DOX + AHE (400)

47.27 ± 0.318a**, b, c

76.83 ± 0.167a, b, c

134.8 ± 0.338a, b, c

60.37 ± 0.578a, b, c

1.193 ± 0.012a, b, c

0.348 ± 0.024b**

DOX + Sily

46.47 ± 0.176a*, b

76.13 ± 0.133a, b

133.1 ± 0.591a, b

58.67 ± 0.333 a, b

1.18 ± 0.015a, b

0.345 ± 0.020b**

  1. Values expressed as mean ± SEM. a Significance at p < 0.0001 Vs. control group, b Significance at p < 0.0001 Vs. Doxorubicin (DOX) group, c Significance at p < 0.0001 of DOX + AHE 400 mg/kg group Vs. DOX + AHE 200 mg/kg group. d Significance at p < 0.0001 of AHE co-treatment groups Vs DOX + Sily group. *, ** Significant difference at p < 0.05 and p < 0.001 respectively. Non-significant difference (p > 0.05) was recorded between control and AHE alone treated group in all parameters. (One way ANOVA followed by Tukey’s multiple comparison tests). Sily-Silymarin